Clinical trials
Adverse Event clinical trials
Below are recruiting adverse event clinical trials, each written for real people, not researchers. We’re tracking 180 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07145918RecruitingPhase 2
Study of an oral schizophrenia drug for adults
This trial tests an experimental oral drug (emraclidine) to see if it helps symptoms of schizophrenia and how it moves through the body. It looks at two groups of participants: those with stable symptoms and those having an acute flare-up.
Little Rock, ArkansasAges 18–65 - NCT07139860Recruiting
AI system for early warning after a heart attack
This study tests an artificial intelligence system that watches for early signs of complications after a heart attack. If you join, the system may help doctors catch problems sooner.
BeijingAges 18 years+ - NCT07098351Recruiting
A trial for a new itchy skin medicine for people on peritoneal dialysis
This trial tests if a medication called nalfurafine hydrochloride (taken as a tablet that melts in your mouth) can help reduce moderate to severe itching in people receiving peritoneal dialysis for chronic kidney disease.
Guangzhou, GuangdongAges 18–85 - NCT07095452RecruitingPhase 2/Phase 3
Newly diagnosed myeloma: comparing drug combinations for non-transplant patients
This trial tests a new combination of two drugs (etentamig and daratumumab) against the current standard of daratumumab plus lenalidomide and dexamethasone in people recently diagnosed with multiple myeloma who cannot have a stem cell transplant. The goal is to see which combination better controls the disease while keeping side effects manageable.
Scottsdale, ArizonaAges 18 years+ - NCT07071532RecruitingPhase 1
Study of ABBV-932 with itraconazole for bipolar disorder
This study tests an investigational drug called ABBV-932 in people with bipolar disorder. It looks at how the drug moves through the body when taken with another medication (itraconazole) and checks for any side effects.
Los Alamitos, CaliforniaAges 18–65 - NCT06519292Recruiting
Heart side effects from immunotherapy in cancer patients
This trial looks at whether immunotherapy drugs (checkpoint inhibitors) cause heart problems in people with certain cancers. It will help doctors understand who is at risk and how to monitor for side effects.
Amsterdam, North HollandAges 50 years+ - NCT07059845RecruitingPhase 2
Studying mirvetuximab combos for ovarian cancer
This trial tests multiple combinations of the drug mirvetuximab soravtansine with other treatments for people with ovarian cancer. It aims to see how well these combos work and what side effects they cause.
La Jolla, CaliforniaAges 18 years+ - NCT07058454Recruiting
Heart safety study for targeted cancer therapies
This study looks at how targeted cancer treatments affect the heart. If you are an adult with any type of cancer and are getting or will get chemotherapy (including targeted drugs), joining this study helps doctors understand heart risks better.
Guangzhou, GuangdongAges 18 years+ - NCT07044687RecruitingPhase 4
Venetoclax with azacitidine for newly diagnosed AML
This trial tests a combination of oral venetoclax and injected azacitidine for adults who are newly diagnosed with acute myeloid leukemia (AML) and cannot have standard strong chemotherapy. The goal is to see how well this treatment works and what side effects it may cause.
Gurgaon, HaryanaAges 18 years+ - NCT07024784RecruitingPhase 2
Study of IMGN151 for gynecologic cancers
This study tests a new drug (IMGN151) given intravenously, alone or with other therapies, for people with certain gynecologic cancers, specifically high-grade serous ovarian, fallopian tube, or primary peritoneal cancer. The goal is to see how well it works and what side effects might occur.
Los Angeles, CaliforniaAges 18 years+ - NCT07024238Enrolling by invitation
Short-chain fatty acid supplement for kidney transplant patients
This study tests whether taking a short-chain fatty acid (a type of fiber-like substance) supplement can improve gut health in people who have had a kidney transplant. It may help keep the transplant working well.
Martin, SlovakiaAges 18 years+ - NCT07023289RecruitingPhase 2
Study of Telisotuzumab Adizutecan for ctDNA-Positive Colorectal Cancer
This trial tests a new drug, Telisotuzumab Adizutecan, given through a vein (infusion) alone or with standard treatments for people with colorectal cancer who have no visible tumors on scans but still have cancer DNA (ctDNA) in their blood after surgery and chemotherapy.
Huntsville, AlabamaAges 18 years+ - NCT07017283Recruiting
Comparing two sedation methods for older adults having ERCP
This study compares two ways of keeping you comfortable and safe during an ERCP procedure: deeper sedation with a breathing tube versus deep sedation without a breathing tube. It aims to find which method causes fewer side effects in older adults.
Hangzhou, ZhijiangAges 60 years+ - NCT07016022Recruiting
Heart and lung test before chest surgery helps predict risks
This study checks if a simple test of your heart and breathing before chest surgery can help predict problems after the operation. It looks at people having surgery for lung, esophagus, stomach, or chest tumors.
Ottawa, OntarioAges 18 years+ - NCT07004452Recruiting
Predicting heart risks in younger adults with early heart disease
This study uses a multi-modal approach to predict adverse events in adults aged 18-45 with premature coronary heart disease. It aims to improve risk prediction and management for younger patients.
BeijingAges 18–45 - NCT07005102RecruitingPhase 2/Phase 3
Telisotuzumab adizutecan and osimertinib for EGFR-positive lung cancer
This trial tests a new drug combination (telisotuzumab adizutecan plus osimertinib) as a first treatment for adults with a specific type of advanced lung cancer that has an EGFR mutation. The goal is to see if the combination is safe and works better than standard care.
Chandler, ArizonaAges 18 years+ - NCT07007065RecruitingPhase 3
Study of a gene therapy for wet age-related macular degeneration
This trial tests a one-time gene therapy injection for wet AMD that may reduce the need for regular eye injections. It is for people who have already responded to anti-VEGF injections but want a longer-lasting treatment.
Mesa, ArizonaAges 50 years+ - NCT06977724RecruitingPhase 1
Testing a new drug for lupus, sjogren's, and rheumatoid arthritis
This study tests an experimental medicine given by IV infusion to see if it is safe and helps reduce symptoms of lupus, sjogren's disease, or rheumatoid arthritis. It is an early-phase trial, so the main goals are checking side effects and how the drug behaves in the body, but it will also look at how well it works.
Avon Park, FloridaAges 18–75 - NCT06953960RecruitingPhase 1/Phase 2
Surzetoclax for multiple myeloma
This trial tests a new oral drug, surzetoclax, given alone or with other myeloma treatments, in adults whose myeloma has come back or stopped responding to treatment. It may help slow the disease and improve symptoms.
Los Angeles, CaliforniaAges 18 years+ - NCT06896916RecruitingPhase 1
Study of etentamig and a CELMoD drug for relapsed multiple myeloma
This trial tests a new combination of two drugs—etentamig given through a vein and a CELMoD pill—for people whose multiple myeloma has come back or stopped responding to treatment. The goal is to see if this combination is safe and helps control the disease.
Beverly Hills, CaliforniaAges 18 years+ - NCT06892522RecruitingPhase 1/Phase 2
T cell therapies for multiple myeloma
This trial tests new antibody treatments for multiple myeloma, given alone or with other drugs. It aims to see if they can control the disease and what side effects might occur.
Duarte, CaliforniaAges 18 years+ - NCT05663775RecruitingPhase 2
Mesalamine to prevent bowel inflammation after melanoma immunotherapy
This study tests whether taking mesalamine can prevent colitis (bowel inflammation) in people with advanced melanoma who are treated with ipilimumab plus nivolumab. It may help reduce dangerous stomach or bowel side effects from this cancer treatment.
Edmonton, AlbertaAges 18 years+ - NCT06858813RecruitingPhase 1
ABBV-324 for advanced liver or lung cancer
This study tests an experimental IV drug (ABBV-324) for adults with advanced liver cancer (HCC) or advanced squamous lung cancer (LUSC). It aims to see if the drug is safe and whether it can help control the disease.
Duarte, CaliforniaAges 18 years+ - NCT06860542RecruitingPhase 2
Inhaled steroid to prevent lung inflammation from returning after immunotherapy
This trial tests whether using an inhaled steroid (budesonide) can help prevent lung inflammation (pneumonitis) from coming back in people who have had it caused by immunotherapy cancer treatment. It may be an option for patients who need extra support after their first bout of this side effect.
Calgary, AlbertaAges 18 years+
Hear when a new Adverse Event trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for adverse event?
- Yes. Clin2 currently lists 180 recruiting adverse event studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a adverse event trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a adverse event trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.